Skip to main content
HRMY
NASDAQ Life Sciences

Harmony Biosciences Unveils Positive Phase 1 Data for Orexin Agonist BP-205, Plans Mid-2027 Phase 2

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$37.05
Mkt Cap
$2.245B
52W Low
$25.52
52W High
$40.87
52W Position info
45% above low
Off High info
9.3% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

HRMY sits 45% above its 52-week low of $25.52 on elevated volume (2.3× avg).

Summary

Harmony Biosciences reported favorable Phase 1 single ascending dose data for BP-205, its orexin-2 receptor agonist, showing good pharmacokinetics and safety. The company plans to initiate Phase 2 studies in multiple CNS indications starting mid-2027. This expands the pipeline beyond the core WAKIX franchise, which just posted record Q2 revenue of $261.3M. The news follows the recent CFO departure and insider selling, but the pipeline progress offers a new growth narrative. The stock rose 8% on the earnings beat and pipeline update, with analysts raising price targets.

At the time of this announcement, HRMY was trading at $37.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.52 to $40.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.94
Real-time Price: $32.43 info
Change: -$3.51 (-10%) info
Market Cap: $1.914B info
HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $32.43 info
Change: -$3.75 (-10%) info
Market Cap: $1.914B info
HRMY
Nov 04, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $32.43 info
Change: -$4.07 (-11%) info
Market Cap: $1.914B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $32.43 info
Change: -$3.60 (-10%) info
Market Cap: $1.914B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $32.43 info
Change: -$5.97 (-16%) info
Market Cap: $1.914B info